Anteris Technologies Files Appendix 3G for New Share Issue
08:04 ETThe $10B TAVR Market Grew. Why Are Most Patients Still Untreated?
Anteris Announces Results for the First Quarter of 2026 | AVR Stock News
Anteris Ends v2vmedtech Development Agreement, Limits Exposure
Anteris Issues 78,740 Unquoted RSUs Under Employee Incentive Plan
Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference